IAM 8-K: SEC filing

Iambic Therapeutics, Inc.

Filed with the SEC on · accession 0001193125-26-462184

IAM filed a 8-K (current report) with the SEC on Nov 16, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Iambic Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

Key details

RegistrantIambic Therapeutics, Inc.
Chief executive officerThomas Miller, Ph.D.

✦ Ask GOAX AI about this filing — what it means for IAM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for IAM?

Click here

Frequently asked questions

What did IAM file with the SEC on Nov 16, 2026?

IAM filed a 8-K (SEC filing). Iambic Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026, furnished under Item 2.02 of Form 8-K.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other IAM SEC filings

Get alerts when IAM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days